Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... using the terms exenatide, liraglutide, albiglutide, and lixisenatide.

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

bInstitute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK Inflammation is probably a key link between obesity and cancer.

Diabetes Care. 2006;29(2):435-449.

Oregon Health & Science University, in collaboration with Oregon State University, has discovered the structural organization ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Nature has developed a unique structure as a scaffold for almost all nerve cells: the membrane-associated periodic skeleton ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.